Phase II

TOKYO, Japan and PRINCETON, New Jersey, Aug. 31/Sept. 1, 2026 Kyowa Kirin Co., Ltd. announced a voluntary agreement with...

LONDON, UK, Sept. 1, 2026 GSK announced that it will advance its investigational mRNA seasonal influenza vaccine candidate into...

NANJING, China — August 25, 2026 Leads Biolabs announced that its proprietary Opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody, has...

NANJING, China, August 20, 2026 Leads Biolabs announced that the full abstract for its Phase II study of LBL-024...

SAN FRANCISCO, Calif., CAMBRIDGE, Mass., & SUZHOU, China, July 14, 2026 Innovent Biologics and Spero Therapeutics have entered into...

LYON, France — May 28, 2026 Brenus Pharma announced that the U.S. Food and Drug Administration has accepted the...

Hong Kong | April 27, 2026 Ascletis Pharma Inc. has announced the successful completion of enrollment in its U.S....